Article Information
History
- March 23, 2020.
Article Versions
- Version 1 (March 20, 2020 - 21:12).
- You are currently viewing Version 2 of this article (March 23, 2020 - 02:09).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Sangeun Jeon1,†,
- Meehyun Ko1,†,
- Jihye Lee1,
- Inhee Choi2,
- Soo Young Byun3,
- Soonju Park3,
- David Shum3 and
- Seungtaek Kim1,*
- 1Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea
- 2Medicinal Chemistry, Institut Pasteur Korea, Seongnam, Korea
- 3Screening Discovery Platform, Institut Pasteur Korea, Seongnam, Korea
- ↵*Corresponding author: Seungtaek Kim, Ph.D., Zoonotic Virus Laboratory, Institut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, South Korea, Tel) 82-31-8018-8230, Fax) 82-31-8018-8014, Email) seungtaek.kim{at}ip-korea.org
Posted March 23, 2020.
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
